Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GLAS · against 259 other Healthcare companies of similar size
Ranked #166 of 260 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score95 peers with a valuation score of 0–9, including GLAS · Click a bar to see the companies
Mainly because of its earnings yield, free cash flow yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | GLAS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 243 reported | -31.6% | -1.1% | 19% | 30% | |
| EBITDA yieldHigher is better · 266 reported | -6.6% | 1.4% | 32% | 50% | |
| Free cash flow yieldHigher is better · 143 reported | -16.8% | -12.2% | 43% | 20% | |
| Book yieldHigher is better · 248 reported | 34.9% | 61.3% | 30% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 166 | 399M USD | 8 | 32 | |
| 166 | 301M USD | 8 | ||
| 166 | 302M USD | 8 | 17 | |
| 166 | 375M USD | 8 | 46 | |
| 166 | 221M USD | 8 | 33 | |
| 166 | 234M USD | 8 | ||
| 166 | 207M USD | 8 | 41 | |
| 166 | 238M USD | 8 | 41 | |
| 166 | 172M USD | 8 | 3 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score